Sigma share price dives 6% on Chemist Warehouse merger hurdle

The proposed merger faces ACCC concerns.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Sigma Healthcare Ltd (ASX: SIG) share price has plunged more than 6% in morning trade on Thursday following news that the Australian Competition and Consumer Commission (ACCC) has raised concerns over its proposed merger with Chemist Warehouse.

Sigma's planned merger with the chemist giant — to be structured as a reverse takeover — has been the subject of ongoing debate since it was announced in December last year.

The Sigma share price has rallied some 50% since then, even with a pullback over the last three months. Here are the details of the ACCC's response and what it means for investors.

A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.

Image source: Getty Images

Sigma Healthcare share price slides as ACCC speaks

Today, the ACCC announced its "preliminary concerns" over the proposed transaction. Investors have reacted swiftly, sending the Sigma share price down sharply in early trade.

According to ACCC commissioner Stephen Ridgeway, the merger represents a major structural change for the pharmacy sector.

He noted the competitive threat to independent pharmacies that might be caused by "the largest pharmacy chain by revenue merging with a key wholesaler".

We have identified a range of preliminary competition concerns, including at the retail level and as a result of the proposed integration of the merged firm across the wholesale and retail level. We want to hear from interested parties, including rival pharmacies as we continue this review.

The ACCC's other primary concern was that the merged entity would become "uniquely vertically integrated". That means the new entity would own its entire supply chain.

This could potentially raise barriers for rivals entering or expanding in the market, leading to higher prices and reduced service quality for consumers.

Even still, the ACCC said its focus was on the acquisition's impact on competition rather than the pros or cons of different business models.

"The key issue is whether or not the proposed acquisition weakens competition in the supply of pharmaceutical products," the ACCC said.

What this means for the Sigma share price we will have to wait and see.

Details of Sigma and Chemist Warehouse merger

Sigma Healthcare is one of the largest wholesalers of prescription medicines in Australia. It also operates as a franchisor of pharmacies. Brands on its books include Amcal +, Discount Drug Stores, PharmaSave, and Guardian.

Chemist Warehouse, on the other hand, is a franchisor and wholesaler.

News of the deal sent the Sigma share price soaring last year.

The proposed acquisition would see Chemist Warehouse shareholders hold a majority 85.75% stake in the newly-listed ASX entity. Sigma shareholders would hold the remaining 14.25%.

The ACCC has not yet concluded the potential competitive impact of the merger. But it has called for submissions from interested parties by June 27 to gather further insights.

The Sigma share price is up nearly 13% this year to date, and has climbed 37% into the green the past 12 months. It reached a 52-week closing high of $1.31 in April.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

2 classy ASX healthcare stocks to buy before the next market surge

If sentiment shifts, these global powerhouses could lead the rally.

Read more »

Two people jump and high five above a city skyline.
Healthcare Shares

Why rebounding Telix shares could still rise 40%

Bell Potter doesn't think it is too late to buy this stock.

Read more »

Female in elegant outfit smiling and gesturing victory with hands.
Healthcare Shares

Are Telix shares a buy after flying 40% higher in March?

Telix shares are up another 5.3% on Tuesday.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces.
Healthcare Shares

Down 30% today, is it time to buy into this beaten-down biotech share?

While there's been bad news, this company has more irons in the fire.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

What's the impact of US tariffs on Aussie drugmakers CSL and Mayne Pharma?

Is the US' bark worse than its bite?

Read more »

Health professional working on his laptop.
Healthcare Shares

Mesoblast shares are back in the red on Tuesday. Here's why

Mesoblast shares slip despite another strong quarterly sales update from Ryoncil.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Earnings Results

Why are Telix shares jumping 8% today?

The radiopharmaceuticals company's shares are starting the week strongly.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Mesoblast shares: Ryoncil® underpins strong earnings growth

Mesoblast shares are in focus as Ryoncil® delivers nearly US$100m in sales since launch, fueling future growth initiatives.

Read more »